ABL1 and Lewy body dementia: Pagan et al. demonstrated that the c-Abl inhibitor Nilotinib penetrates the blood-brain barrier and improves the clinical outcomes of patients suffering from PD with dementia (PDD) and dementia with Lewy bodies (DLB) [18].